TFF Pharmaceuticals Appoints Michael Patane, Ph D , to Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | Daily Herald dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 08, 2021
Silvia Buonamici, Ph.D.,
BOSTON (BUSINESS WIRE) Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the appointments of Owen Wallace, Ph.D., as Chief Scientific Officer and Silvia Buonamici, Ph.D., as Senior Vice President, Drug Discovery Biology, as the company continues to expand its executive leadership team. Drs. Wallace and Buonamici will oversee the research and development of the company’s pipeline of molecular glue degrader programs.
“As we continue to build out the Monte Rosa team and advance multiple new therapies toward clinical development, we are thrilled to welcome Owen and Silvia to the team,” said Monte Rosa CEO Markus Warmuth, M.D. “Owen brings more than two decades of experience leading drug discovery and development and will be a significant asset to the team as we bring our protein degrader therapies into cl